About Filsuvez

Fits into daily routines¹

At-home application empowers patients and caregivers to take control of wound care

Used wherever it’s needed¹

With no limitation on wound area coverage, FILSUVEZ can be applied to every wound, at every dressing change*

Compatible with other wound care management^1†

There are no known contraindications to FILSUVEZ

FDA-approved for both
DEB and JEB¹

FILSUVEZ is appropriate for a broad range of patients with DEB and JEB

*Do not use FILSUVEZ in or around the eyes or mucous membranes (mouth, vagina, or anus). If accidental contact does occur, immediately wash the area with clean water and contact your doctor if you have any discomfort.¹

^†Includes standard wound care dressing types, petroleum jelly, and other over-the-counter ointments and creams.

DEB, dystrophic epidermolysis bullosa; JEB, junctional epidermolysis bullosa.

See the before and after images of wounds treated with FILSUVEZ²

Images

This image depicts the wound of a real patient with recessive dystrophic EB before and after treatment with FILSUVEZ in the EASE trial. Image used with permission.

Explore the impact FILSUVEZ has on patients

Efficacy

Henry, FILSUVEZ patient.

Important Safety Information

Warnings & Precautions

Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Important Safety Information

Warnings & Precautions

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Choose FILSUVEZ as a core part of your comprehensive dystrophic or junctional epidermolysis bullosa wound care plan

Important Safety Information & Indication

Important Safety Information

Indication

Important Safety Information & Indication

Important Safety Information

Indication